Orexo AB
STO:ORX

Watchlist Manager
Orexo AB Logo
Orexo AB
STO:ORX
Watchlist
Price: 19.78 SEK 6.92%
Market Cap: 686.6m SEK

Relative Value

The Relative Value of one ORX stock under the Base Case scenario is 36.2 SEK. Compared to the current market price of 19.78 SEK, Orexo AB is Undervalued by 45%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ORX Relative Value
Base Case
36.2 SEK
Undervaluation 45%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
50
vs Industry
72
Median 3Y
0.9
Median 5Y
1.1
Industry
2.5
Forward
1.2
vs History
vs Industry
Median 3Y
-3.5
Median 5Y
-3.7
Industry
21.5
Forward
-6.5
vs History
4
vs Industry
Median 3Y
-4
Median 5Y
-3.8
Industry
16.6
vs History
vs Industry
Median 3Y
-2.9
Median 5Y
-3.3
Industry
24.9
vs History
vs Industry
7
Median 3Y
2.9
Median 5Y
2.8
Industry
2.1
vs History
33
vs Industry
61
Median 3Y
1.3
Median 5Y
1.4
Industry
2.7
Forward
1.8
vs History
31
vs Industry
74
Median 3Y
1.6
Median 5Y
1.7
Industry
5.2
vs History
11
vs Industry
25
Median 3Y
-5
Median 5Y
-5
Industry
12.8
Forward
90.9
vs History
vs Industry
Median 3Y
-4.9
Median 5Y
-5.6
Industry
16.3
Forward
-34.2
vs History
4
vs Industry
Median 3Y
-4.9
Median 5Y
-4.8
Industry
14.9
vs History
vs Industry
Median 3Y
-4.8
Median 5Y
-4.8
Industry
17.9
vs History
3
vs Industry
34
Median 3Y
1.2
Median 5Y
1.4
Industry
1.9

Multiples Across Competitors

ORX Competitors Multiples
Orexo AB Competitors

Market Cap P/S P/E EV/EBITDA EV/EBIT
SE
Orexo AB
STO:ORX
682.5m SEK 1.1 -3.3 26.4 -7.3
US
Eli Lilly and Co
NYSE:LLY
733.3B USD 15 66 35.5 38.8
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
373.4B USD 4.2 17.1 12.5 16.4
DK
Novo Nordisk A/S
CSE:NOVO B
2.2T DKK 7.2 20.8 14.4 16.5
CH
Roche Holding AG
SIX:ROG
213.3B CHF 3.5 25.8 9.7 11.3
CH
Novartis AG
SIX:NOVN
190.2B CHF 4.3 18 10.6 14.2
UK
AstraZeneca PLC
LSE:AZN
167B GBP 4.1 29.1 131.1 197.7
US
Merck & Co Inc
NYSE:MRK
199.6B USD 3.1 11.4 8.5 10.3
IE
Endo International PLC
LSE:0Y5F
163.5B USD 70.5 -56 261.3 655.3
US
Pfizer Inc
NYSE:PFE
136.3B USD 2.2 17.3 7.4 10.5
P/E Multiple
Earnings Growth PEG
SE
Orexo AB
STO:ORX
Average P/E: 25.7
Negative Multiple: -3.3
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
66
50%
1.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
17.1
27%
0.6
DK
Novo Nordisk A/S
CSE:NOVO B
20.8
18%
1.2
CH
Roche Holding AG
SIX:ROG
25.8
32%
0.8
CH
Novartis AG
SIX:NOVN
18
17%
1.1
UK
AstraZeneca PLC
LSE:AZN
29.1
36%
0.8
US
Merck & Co Inc
NYSE:MRK
11.4
17%
0.7
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -56 N/A N/A
US
Pfizer Inc
NYSE:PFE
17.3
31%
0.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
SE
Orexo AB
STO:ORX
Average EV/EBITDA: 396.7
26.4
-15%
N/A
US
Eli Lilly and Co
NYSE:LLY
35.5
30%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.5
7%
1.8
DK
Novo Nordisk A/S
CSE:NOVO B
14.4
13%
1.1
CH
Roche Holding AG
SIX:ROG
9.7
5%
1.9
CH
Novartis AG
SIX:NOVN
10.6
5%
2.1
UK
AstraZeneca PLC
LSE:AZN
131.1
10%
13.1
US
Merck & Co Inc
NYSE:MRK
8.5
8%
1.1
IE
E
Endo International PLC
LSE:0Y5F
261.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.4
2%
3.7
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
SE
Orexo AB
STO:ORX
Average EV/EBIT: 1 867.3
Negative Multiple: -7.3
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
38.8
32%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.4
13%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
16.5
14%
1.2
CH
Roche Holding AG
SIX:ROG
11.3
6%
1.9
CH
Novartis AG
SIX:NOVN
14.2
10%
1.4
UK
AstraZeneca PLC
LSE:AZN
197.7
23%
8.6
US
Merck & Co Inc
NYSE:MRK
10.3
11%
0.9
IE
E
Endo International PLC
LSE:0Y5F
655.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.5
10%
1